Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.003
Sell
RSI(14)
44.549
Neutral
STOCH(KDJ)(9,3,3)
40.178
Sell
ATR(14)
0.099
Low Volatility
CCI(14)
0.710
Neutral
Williams %R
62.500
Sell
TRIX(12,20)
-0.072
Sell
StochRSI(14)
15.709
Sell
Search
Stereotaxis Inc
STXSAdd to Watchlist
1.850USD
-0.085-4.38%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
180.81MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Stereotaxis Inc
Currency: USD Updated: 2026-05-15Key Insights
Stereotaxis Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 107 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.10.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Stereotaxis Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Stereotaxis Inc Highlights
StrengthsRisks
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 20.94% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 32.38M.
Fairly Valued
The company’s latest PE is -7.57, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 49.70M shares, increasing 4.31% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 6.96K shares of this stock.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
4.100
Target Price
+111.34%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Stereotaxis Inc is 6.19, ranking 160 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 6.29M, representing a year-over-year decrease of 15.81%, while its net profit experienced a year-over-year decrease of 0.57%.
Score
Financials
6.03
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.10
Operational Efficiency
5.15
Growth Potential
5.61
Shareholder Returns
7.08
Stereotaxis Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Stereotaxis Inc is 6.86, ranking 140 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -7.57, which is -31.72% below the recent high of -5.17 and -66.21% above the recent low of -12.58.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 107/206
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Stereotaxis Inc is 8.00, ranking 66 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 4.00, with a high of 5.00 and a low of 4.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
4.100
Target Price
+121.62%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
93
Total
4
Median
7
Average
Company name
Ratings
Analysts
Stereotaxis Inc
STXS
5
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
35
Edwards Lifesciences Corp
EW
34
Veeva Systems Inc
VEEV
33
Thermo Fisher Scientific Inc
TMO
31
1
2
3
...
19
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Stereotaxis Inc is 6.83, ranking 83 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 1.99 and the support level at 1.73, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.888
Sell
MA10
1.898
Sell
MA20
1.906
Sell
MA50
1.903
Sell
MA100
2.117
Sell
MA200
2.417
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Stereotaxis Inc is 5.00, ranking 110 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 50.99%, representing a quarter-over-quarter increase of 8.27%. The largest institutional shareholder is James Simons, holding a total of 372.60K shares, representing 0.38% of shares outstanding, with 169.15% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Stereotaxis Inc is 2.88, ranking 139 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.34. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.33
VaR
+5.88%
240-Day Maximum Drawdown
+50.14%
240-Day Volatility
+62.85%
Return
Best Daily Return
60 days
+5.73%
120 days
+8.05%
5 years
+33.14%
Worst Daily Return
60 days
-6.39%
120 days
-6.50%
5 years
-26.46%
Sharpe Ratio
60 days
-0.67
120 days
-0.63
5 years
-0.16
Risk Assessment
Maximum Drawdown
240 days
+50.14%
3 years
+50.14%
5 years
+84.36%
Return-to-Drawdown Ratio
240 days
-0.34
3 years
+0.13
5 years
-0.19
Skewness
240 days
+0.25
3 years
+0.73
5 years
+0.53
Volatility
Realised Volatility
240 days
+62.85%
5 years
+71.90%
Standardised True Range
240 days
+6.90%
5 years
+9.04%
Downside Risk-Adjusted Return
120 days
-111.86%
240 days
-111.86%
Maximum Daily Upside Volatility
60 days
+37.99%
Maximum Daily Downside Volatility
60 days
+37.07%
Liquidity
Average Turnover Rate
60 days
+0.49%
120 days
+0.54%
5 years
--
Turnover Deviation
20 days
-14.54%
60 days
-2.90%
120 days
+7.47%
Peer Comparison
Healthcare Equipment & Supplies
Stereotaxis Inc
STXS
6.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
ANIK
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LIVN
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
TMO
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bruker Corp
BRKR
8.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
